The therapeutic potential of EVs-mediated interfering RNA (siRNA) delivery was firstly demonstrated by the knockdown of BACE1, a therapeutic target of AD, in EVs derived from autologous dendritic cells. The gene discussed is BACE1; the disease is Alzheimer disease.